EGFR-Mutated NSCLC: Clinical Practice Assessment and Gap Analysis

被引：0
|
作者：
Herrmann, Tara [1 ]
Hamarstrom, Elaine [2 ]
Ramalingam, Suresh [3 ]
机构：
[1] Medscape Educ, Ft Sam Houston, TX USA
[2] Medscape Educ, New York, NY USA
[3] Emory Univ, Winship Canc Inst, Med Oncol, Atlanta, GA 30322 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
EGFR; T790M; Education; molecular testing;
D O I：
10.1016/j.jtho.2016.11.1716
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.02b-049
引用
收藏
页码：S1218 / S1219
页数：2
相关论文
共 50 条
  • [21] Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC
    Banna, Giuseppe Luigi
    Addeo, Alfredo
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (16): : 1555 - 1556
  • [22] MET amplification increases the metastatic spread of EGFR-mutated NSCLC
    Baldacci, Simon
    Kherrouche, Zoulika
    Cockenpot, Vincent
    Stoven, Luc
    Copin, Marie Christine
    Werkmeister, Elisabeth
    Marchand, Nathalie
    Kyheng, Maeva
    Tulasne, David
    Cortot, Alexis B.
    LUNG CANCER, 2018, 125 : 57 - 67
  • [23] Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
    Jiang, Tao
    Xu, Xiaobo
    Chen, Xiaojuan
    Ding, Ning
    Hu, Qin
    Zhou, Caicun
    Hu, Jie
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (06) : 2514 - 2517
  • [24] Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
    Qiao, Meng
    Jiang, Tao
    Liu, Xinyu
    Mao, Shiqi
    Zhou, Fei
    Li, Xuefei
    Zhao, Chao
    Chen, Xiaoxia
    Su, Chunxia
    Ren, Shengxiang
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (08) : 1267 - 1288
  • [25] Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC
    Lu, Shun
    Kato, Terufumi
    Dong, Xiaorong
    Ahn, Myung-Ju
    Quang, Le-Van
    Soparattanapaisarn, Nopadol
    Inoue, Takako
    Wang, Chih-Liang
    Huang, Meijuan
    Yang, James Chih-Hsin
    Cobo, Manuel
    Ozguroglu, Mustafa
    Casarini, Ignacio
    Khiem, Dang-Van
    Sriuranpong, Virote
    Cronemberger, Eduardo
    Takahashi, Toshiaki
    Runglodvatana, Yotsawaj
    Chen, Ming
    Huang, Xiangning
    Grainger, Ellie
    Ghiorghiu, Dana
    van der Gronde, Toon
    Ramalingam, Suresh S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024,
  • [26] Osimertinib also improves overall survival in EGFR-mutated NSCLC
    Lichert, Frank
    PNEUMOLOGIE, 2024, 78 (03): : 143 - 143
  • [27] Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
    Ramalingam, S. S.
    Vansteenkiste, J.
    Planchard, D.
    Cho, B. C.
    Gray, J. E.
    Ohe, Y.
    Zhou, C.
    Reungwetwattana, T.
    Cheng, Y.
    Chewaskulyong, B.
    Shah, R.
    Cobo, M.
    Lee, K. H.
    Cheema, P.
    Tiseo, M.
    John, T.
    Lin, M-C
    Imamura, F.
    Kurata, T.
    Todd, A.
    Hodge, R.
    Saggese, M.
    Rukazenkov, Y.
    Soria, J-C
    Boyer, Michael
    Lee, Chee
    Hughes, Brett
    O'Byrne, Kenneth
    Briggs, Peter
    Milward, Michael
    John, Thomas
    Demedts, Ingel
    Vansteenkiste, Johan
    Bustin, Frederique
    Barrios, Carlos Henrique
    Timcheva, Constanta
    Butts, Charles
    Goss, Glenwood
    Juergens, Rosalyn
    Leighl, Natasha
    Cheng, Susanna
    Burkes, Ronald
    Zhou, Caicun
    Zhang, Helong
    Shu, Yongqian
    Cheng, Ying
    Zhou, Qing
    Li, Wei
    Feng, Guosheng
    He, Yong
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01): : 41 - 50
  • [28] Chemotherapy in EGFR-mutated NSCLC: optimizing combinations with TKIs and amivantamab
    Rosell, Rafael
    Gonzalez-Cao, Maria
    NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (03) : 169 - 170
  • [29] Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis
    Yu, Zhuchen
    Xu, Fei
    Zou, Juntao
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (04) : 505 - 517
  • [30] Feasibility and safety of EGFR-TKI neoadjuvant therapy for EGFR-mutated NSCLC: A meta-analysis
    Zhuchen Yu
    Fei Xu
    Juntao Zou
    European Journal of Clinical Pharmacology, 2024, 80 : 505 - 517
12345